Status:
UNKNOWN
Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Erythropoietin, EPO, is the main regulator and stimulator of bone marrow erythropoiesis, and is responsible for growth and differentiation of the erythroid cell lineage. Our team, in collaboration wit...
Detailed Description
Background: Erythropoietin, EPO, is the main regulator and stimulator of bone marrow erythropoiesis, and is responsible for growth and differentiation of the erythroid cell lineage. The cloning of the...
Eligibility Criteria
Inclusion
- Adult (more than 17 years old)
- With one of next cancer types: breast, lung, colon, head, neck and lymphoma
- I prospective part only: that signed ICF
Exclusion
- Teenagers below 18 years old
- In prospective part: that did not sign ICF
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2016
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01827514
Start Date
January 1 2013
End Date
January 1 2016
Last Update
April 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel